Screener
Viridian Therapeutics, Inc. VRDN Business Segments — Operating Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|---|---|
| Segment research and development expense (a) | $64,189 | $81,401 | $135,933 | $152,439 |
| Segment selling, general and administrative expense (a) | 45,262 | 14,483 | 76,317 | 27,047 |
| Share-based compensation expense (see Note 11) | 16,984 | 10,844 | 30,374 | 21,064 |
| Total operating expenses, excluding depreciation expense | 126,435 | 106,728 | 242,624 | 200,550 |
| License revenue | 180 | — | 186 | — |
| Other items (b) | 504 | (5,993) | (10,790) | (12,903) |
| Consolidated net loss | $127,119 | $100,735 | $232,020 | $187,647 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s business segments — operating expenses?
- Viridian Therapeutics, Inc. (VRDN) reported business segments — operating expenses of $126.44M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s business segments — operating expenses changed year-over-year?
- Viridian Therapeutics, Inc.'s business segments — operating expenses increased by 18.5% year-over-year, from $106.73M to $126.44M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s business segments — operating expenses?
- Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s business segments — operating expenses has grown at a 47.2% compound annual growth rate (CAGR), from $136.08M to $433.78M.
- What does business segments — operating expenses mean?
- This metric aggregates all costs incurred by the business segment to conduct its primary operations, including research, development, and administrative functions. It provides a comprehensive view of the total burn rate required to sustain the segment's activities during the clinical development phase. Analyzing this figure is essential for evaluating the segment's operational scale and resource consumption.
Ask your AI about Viridian Therapeutics, Inc.'s business segments — operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude